CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising

CytomX Therapeutics has filed a $250M mixed securities shelf, allowing the company to raise funds through various means such as debt and equity offerings. This move is aimed at providing flexibility to the company in case of any future funding requirements.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced the filing of a $250 million mixed securities shelf registration, allowing the company to raise funds through various means such as debt and equity offerings. This strategic move aims to provide the company with flexibility in meeting future funding requirements.

The company's latest financial results, released on August 7, 2025, highlighted the progress made in its clinical pipeline, including positive interim data from the Phase 1 study of CX-2051, an EpCAM Antibody Drug Conjugate (ADC) in patients with advanced colorectal cancer (CRC). The company also announced plans to initiate a Phase 2 study in CRC in the first half of 2026. Additionally, a combination dose escalation of CX-801, a PROBODY Interferon alpha-2b, with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma has been initiated.

CytomX ended the second quarter of 2025 with $158.1 million in cash, cash equivalents, and investments, providing an expected cash runway to the second quarter of 2027. The company's total revenue for the quarter ended June 30, 2025, was $18.7 million, down from $25.1 million in the same period last year. This decrease was primarily driven by the completion of performance obligations in the Bristol Myers Squibb collaboration, the decision not to further develop the CX-904 program in the Amgen agreement, and a decrease in Moderna activities due to budget considerations.

The company's total operating expense in the second quarter of 2025 was $19.9 million, down from $33.6 million in the same period last year. Research and development expenses were $13.3 million, a decrease of $11.9 million compared to the corresponding period of 2024. General and administrative expenses were $6.6 million, down from $8.4 million in the same period last year.

The filing of the $250 million mixed securities shelf registration is a proactive measure to ensure that CytomX has the financial resources needed to continue its clinical development and research activities. This move also demonstrates the company's commitment to maintaining a strong financial position as it advances its pipeline of novel, conditionally activated biologics.

For more information about CytomX and its latest developments, visit www.cytomx.com.

References:
[1] https://www.globenewswire.com/news-release/2025/08/07/3129715/37704/en/CytomX-Therapeutics-Announces-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html